Immunotherapy for metastatic colorectal cancer: present status and new options
/in Colorectal Cancer, Dendritic Cells, International PublicationsThe dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma
/in Dendritic Cells, International Publications, Malignant MelanomaClinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsA novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer
/in Breast Cancer, Dendritic Cells, International Publications[Prostate carcinoma: vaccination as a new option for treatment]
/in Dendritic Cells, International Publications, Prostate CancerImmunotherapy of lung adenocarcinoma patient with Peptide-pulsed dendritic cells: a case report
/in Dendritic Cells, International Publications, NSCLCImmunotherapy for glioma: getting closer to the clinical arena?
/in Dendritic Cells, Glioblastoma, International PublicationsDevelopment of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
/in Dendritic Cells, International Publications, Prostate CancerTherapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer